From real-world deployment to European validation.
A trajectory, described honestly — not a presence, not a plan with dates, and not a claim about European regulation.
AZ54 does not operate in Europe. No product of ours is available in a European market, we hold no European authorization, licence or certification of any kind, and nothing on this page should be read as a commitment or a date. What follows is what we would need to do, and why we think the ground work transfers.
Why deployment in Africa is relevant here.
Infrastructure built where connectivity is intermittent, where the pharmacy is the first point of contact and where margins per transaction are thin has been forced to be small, resilient and cheap to run. Those are not exotic properties. They are what a European health system asks of a supplier once the pilot is over.
What adapting would actually require.
All three are intent, not work in progress. None is scheduled, and none is a claim.
Interoperability
European health systems exchange data through established standards and national frameworks. Speaking them is an engineering programme, not a configuration flag.
Data governance
The private / shared / open model would have to be reconciled with European data protection law, in its national implementations. We claim no GDPR compliance today.
Regulatory routes
Payment activity is executed by licensed institutions, and any screening capability would face its own regulatory route. Both are questions to answer before entering a market, not after.
The order it would happen in.
A partner and a use case
A European organization with a real pathway and a reason to want this.
A regulatory answer
The route settled with counsel and the relevant authority before anything ships.
A bounded pilot
One site, one capability, measured.
Adaptation, then scale
Interoperability and governance work done properly, once the pilot has shown it is worth doing.
No dates. A sequence is not a schedule, and we will not print one we cannot hold.
For French and European public funders.
Current
What is already proven
Infrastructure in production in 10 markets, with revenue, real users and health outcomes counted in the field.
Target
What is being asked for
Support for the adaptation work itself: interoperability, governance and the regulatory route.
Potential
What is not claimed
No European operation, no certification, no authorization, and no market entry date.
If Europe is your question, start with what exists.
We would rather show a deployment that runs than a European roadmap that does not.